| Pharmaceutical Information |
| Drug Name |
Naloxegol |
| Drug ID |
BADD_D02467 |
| Description |
Naloxegol, for "PEGylated naloxol" is a peripherally-selective opioid antagonist developed by AstraZeneca. It was approved by the FDA in September 2014 and is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non‑cancer pain. The advantage of naloxegol over the opioid antagonist naloxone is that its PEGylated structure allows for high selectivity for peripheral opioid receptors and lack of entry into the central nervous system through the blood-brain barrier. |
| Indications and Usage |
Indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain. |
| Marketing Status |
approved |
| ATC Code |
A06AH03 |
| DrugBank ID |
DB09049
|
| KEGG ID |
D10479
|
| MeSH ID |
C000589308
|
| PubChem ID |
56959087
|
| TTD Drug ID |
D07LCF
|
| NDC Product Code |
24584-1116; 24584-1115 |
| UNII |
44T7335BKE
|
| Synonyms |
naloxegol | Movantik | NKTR-118 |
|
| Chemical Information |
| Molecular Formula |
C34H53NO11 |
| CAS Registry Number |
854601-70-0 |
| SMILES |
COCCOCCOCCOCCOCCOCCOCCOC1CCC2(C3CC4=C5C2(C1OC5=C(C=C4)O)CCN3CC=C)O |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
